{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:24:15Z","timestamp":1778207055400,"version":"3.51.4"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vph.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T21:55:59Z","timestamp":1504734959000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system"],"prefix":"10.1016","volume":"100","author":[{"given":"Kai G.","family":"Kahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mechthild","family":"Westhoff-Bleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tillmann H.C.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1176\/ajp.126.4.470","article-title":"The mortality experience of a population with psychiatric illness","volume":"126","author":"Babigian","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.173.1.11","article-title":"Excess mortality of mental disorder","volume":"173","author":"Harris","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/wps.20382","article-title":"Excess mortality in severe mental disorder: the need for an integrated approach","volume":"16","author":"Ivbijaro","year":"2017","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S2045796014000742","article-title":"Excess mortality, mental illness and global burden of disease","volume":"24","author":"Lawrence","year":"2015","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/wps.20384","article-title":"Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas","volume":"16","author":"Liu","year":"2017","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0030","doi-asserted-by":"crossref","first-page":"e0152223","DOI":"10.1371\/journal.pone.0152223","article-title":"Excess mortality in patients with severe mental disorders in 1996\u20132010 in Finland","volume":"11","author":"Lumme","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vph.2017.09.001_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11920-014-0499-z","article-title":"Excess mortality in bipolar disorders","volume":"16","author":"Miller","year":"2014","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0040","doi-asserted-by":"crossref","first-page":"e55176","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2017.09.001_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.genhosppsych.2015.12.003","article-title":"Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey","volume":"39","author":"Pratt","year":"2016","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"10","key":"10.1016\/j.vph.2017.09.001_bb0050","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1745-0179-4-23","article-title":"Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services","volume":"4","author":"Tidemalm","year":"2008","journal-title":"Clin. Pract. Epidemiol. Ment. Health"},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"177","key":"10.1016\/j.vph.2017.09.001_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2307\/2277862","article-title":"Life tables for patients with mental disease","volume":"27","author":"Malzberg","year":"1932","journal-title":"J. Am. Stat. Assoc."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wps.20128","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1192\/bjp.bp.114.149112","article-title":"Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia","volume":"206","author":"Fekadu","year":"2015","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.vph.2017.09.001_bb0080","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/00325481.2016.1221319","article-title":"Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults","volume":"128","author":"Ho","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.vph.2017.09.001_bb0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"12","key":"10.1016\/j.vph.2017.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.vph.2017.09.001_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1192\/bjp.bp.110.085100","article-title":"Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders","volume":"199","author":"Wahlbeck","year":"2011","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/bjp.bp.112.112169","article-title":"Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both","volume":"202","author":"Cuijpers","year":"2013","journal-title":"Br. J. Psychiatry"},{"issue":"15","key":"10.1016\/j.vph.2017.09.001_bb0105","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","author":"Brown","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/eurpub\/ckv245","article-title":"Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987\u20132010","volume":"26","author":"Osby","year":"2016","journal-title":"Eur. J. Pub. Health"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","article-title":"Estimating the true global burden of mental illness","volume":"3","author":"Vigo","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.vph.2017.09.001_bb0125","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4088\/JCP.v68n0612","article-title":"Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia","volume":"68","author":"Laursen","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0130","first-page":"A42","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Prev. Chronic Dis."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5694\/mja16.00650","article-title":"Cardiovascular disease in patients with schizophrenia","volume":"206","author":"Kritharides","year":"2017","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.vph.2017.09.001_bb0140","doi-asserted-by":"crossref","first-page":"f2539","DOI":"10.1136\/bmj.f2539","article-title":"The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers","volume":"346","author":"Lawrence","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1176\/ps.2009.60.2.147","article-title":"Premature mortality from general medical illnesses among persons with bipolar disorder: a review","volume":"60","author":"Roshanaei-Moghaddam","year":"2009","journal-title":"Psychiatr. Serv."},{"issue":"Suppl","key":"10.1016\/j.vph.2017.09.001_bb0150","first-page":"S67","article-title":"Medical comorbidity in schizophrenia","volume":"178","author":"Lambert","year":"2003","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1440-1614.2001.00877.x","article-title":"Cardiovascular risk factors for people with mental illness","volume":"35","author":"Davidson","year":"2001","journal-title":"Aust. N Z J Psychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0160","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1192\/bjp.183.6.534","article-title":"Scottish schizophrenia lifestyle G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study","volume":"183","author":"McCreadie","year":"2003","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.vph.2017.09.001_bb0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000350094","article-title":"Molecular mechanisms of depression: perspectives on new treatment strategies","volume":"31","author":"Lang","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"issue":"11","key":"10.1016\/j.vph.2017.09.001_bb0170","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.amjmed.2016.05.018","article-title":"Mental health and cardiovascular disease","volume":"129","author":"Chaddha","year":"2016","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.vph.2017.09.001_bb0175","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/CIR.0000000000000019","article-title":"Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association","volume":"129","author":"Lichtman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.09.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)32380-7","article-title":"Socioeconomic status and the 25\u00d725 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women","author":"Stringhini","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ajhg.2013.01.001","volume":"92","author":"Andreassen","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpsychires.2010.04.027","article-title":"Heart disease treatment and mortality in schizophrenia and bipolar disorder - changes in the Danish population between 1994 and 2006","volume":"45","author":"Laursen","year":"2011","journal-title":"J. Psychiatr. Res."},{"issue":"4 Suppl","key":"10.1016\/j.vph.2017.09.001_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1359786810382058","article-title":"Inequalities in healthcare provision for people with severe mental illness","volume":"24","author":"Lawrence","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.vph.2017.09.001_bb0200","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3109\/01612840.2013.832826","article-title":"Physical health inequities in people with severe mental illness: identifying initiatives for practice change","volume":"34","author":"Cunningham","year":"2013","journal-title":"Issues Ment. Health Nurs."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0210","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/s-0038-1656241","article-title":"There an enhancing effect of neuroleptic drugs on blood coagulation and thrombosis","volume":"13","author":"Astrup","year":"1965","journal-title":"Thromb. Diath. Haemorrh."},{"issue":"8","key":"10.1016\/j.vph.2017.09.001_bb0215","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1681.2007.04650.x","article-title":"In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation","volume":"34","author":"Axelsson","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/fca.12.39","article-title":"Blood pressure, fluid retention and the cardiovascular risk of drugs","volume":"8","author":"Blankfield","year":"2012","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.vph.2017.09.001_bb0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fnins.2015.00297","article-title":"Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management","volume":"9","author":"Ventriglio","year":"2015","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3233\/JAD-160828","article-title":"Psychotropic polypharmacy in patients with dementia: prevalence and predictors","volume":"56","author":"Norgaard","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0235","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00019442-200209000-00015","article-title":"Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network","volume":"10","author":"Colenda","year":"2002","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0240","series-title":"US Food and Drug Administration Warning on Antipsychotic Drugs","author":"Rights CCoH","year":"2008"},{"key":"10.1016\/j.vph.2017.09.001_bb0245","series-title":"Public Assessment Report on Antipsychotics and Cerebrovascular Accident","author":"(PhVWP) EPWP","year":"2006"},{"key":"10.1016\/j.vph.2017.09.001_bb0250","series-title":"FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs News Release","author":"FDA","year":"2008"},{"issue":"22","key":"10.1016\/j.vph.2017.09.001_bb0255","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2017.09.001_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1227","article-title":"Exposure to antipsychotics and risk of stroke: self controlled case series study","volume":"337","author":"Douglas","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0265","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.4088\/JCP.15m10303","article-title":"Antipsychotic drug interactions and mortality among nursing home residents with cognitive impairment","volume":"78","author":"Liperoti","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.vph.2017.09.001_bb0270","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40266-012-0013-4","article-title":"Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study","volume":"29","author":"Chatterjee","year":"2012","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.vph.2017.09.001_bb0275","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/jcp.0b013e31815a2531","article-title":"Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users","volume":"27","author":"Barnett","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0280","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S1041610205002280","article-title":"Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics","volume":"17","author":"Finkel","year":"2005","journal-title":"Int. Psychogeriatr."},{"issue":"7489","key":"10.1016\/j.vph.2017.09.001_bb0285","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study","volume":"330","author":"Gill","year":"2005","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119931","article-title":"Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea","volume":"10","author":"Shin","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/JCP.0b013e31827934a4","article-title":"Adverse events in elderly users of antipsychotic pharmacotherapy in the province of Manitoba: a retrospective cohort study","volume":"33","author":"Vasilyeva","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0300","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mpr.1509","article-title":"Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia","volume":"25","author":"Rao","year":"2016","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euroneuro.2017.01.002","article-title":"Benefits and harms of atypical antipsychotics for agitation in adults with dementia","volume":"27","author":"Farlow","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0310","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1254\/jphs.QT-C13","article-title":"QT PRODACT: usability of miniature pigs in safety pharmacology studies: assessment for drug-induced QT interval prolongation","volume":"99","author":"Kano","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.vph.2017.09.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116684337","article-title":"Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion","author":"Acciavatti","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0320","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/14740338.2016.1161021","article-title":"Cardiovascular safety of antipsychotics: a clinical overview","volume":"15","author":"Polcwiartek","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/hup.2540","article-title":"First-generation antipsychotics and QTc: any role for mediating variables?","volume":"31","author":"Carra","year":"2016","journal-title":"Hum. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148212","article-title":"Antipsychotic dose mediates the association between polypharmacy and corrected QT interval","volume":"11","author":"Barbui","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/070674371506000503","article-title":"Antipsychotic polypharmacy and corrected QT interval: a systematic review","volume":"60","author":"Takeuchi","year":"2015","journal-title":"Can. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0340","first-page":"1269","article-title":"Antipsychotic medication and QT prolongation","volume":"31","author":"Chohan","year":"2015","journal-title":"Pak. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0345","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.pra.0000450319.21859.6d","article-title":"QTc prolongation with antipsychotics: is routine ECG monitoring recommended?","volume":"20","author":"Shah","year":"2014","journal-title":"J. Psychiatr. Pract."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01720610-201302000-00002","article-title":"Prolongation: a critical adverse effect of some medications","volume":"26","author":"DeDea","year":"2013","journal-title":"JAAPA"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0365","article-title":"Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: a nation-wide case-crossover study","volume":"4","author":"CS","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"22","key":"10.1016\/j.vph.2017.09.001_bb0370","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"9225","key":"10.1016\/j.vph.2017.09.001_bb0375","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(05)74504-9","article-title":"Antipsychotic drugs and venous thromboembolism","volume":"356","author":"Knudson","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0380","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004850-200309000-00008","article-title":"Olanzapine and venous thromboembolism","volume":"18","author":"Hagg","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9253","key":"10.1016\/j.vph.2017.09.001_bb0385","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0140-6736(05)71522-1","article-title":"Antipsychotic drugs and venous thromboembolism","volume":"357","author":"Hardwick","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients","volume":"62","author":"Maly","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1440-1819.2004.01284.x","article-title":"Two cases of deep vein thrombosis associated with antipsychotic drug use","volume":"58","author":"Matsumoto","year":"2004","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0400","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pnpbp.2004.08.010","article-title":"Left atrial thrombosis associated with antipsychotic drugs","volume":"29","author":"Numata","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0405","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-979493","article-title":"Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy","volume":"30","author":"Pantel","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.vph.2017.09.001_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0415","first-page":"205","article-title":"Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism","volume":"88","author":"Ray","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0420","first-page":"175","article-title":"Thrombotic complications of treatment with antipsychotic drugs","volume":"104","author":"Shulman","year":"2013","journal-title":"Minerva Med."},{"issue":"8","key":"10.1016\/j.vph.2017.09.001_bb0425","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1742-1241.2010.02435.x","article-title":"The importance of venous thromboembolism - a physical consequence of psychiatric treatments","volume":"64","author":"Stansby","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.vph.2017.09.001_bb0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1192\/bjp.179.1.63","article-title":"Antipsychotic medication and venous thrombosis","volume":"179","author":"Thomassen","year":"2001","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0435","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/jnp.2009.21.3.343a","article-title":"Cerebral venous sinus thrombosis may be associated with clozapine","volume":"21","author":"Werring","year":"2009","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"9237","key":"10.1016\/j.vph.2017.09.001_bb0440","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vph.2017.09.001_bb0445","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00023210-200216110-00005","article-title":"Antipsychotic-induced venous thromboembolism: a review of the evidence","volume":"16","author":"Hagg","year":"2002","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"issue":"9618","key":"10.1016\/j.vph.2017.09.001_bb0455","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0460","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.vph.2017.09.001_bb0465","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. Second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.vph.2017.09.001_bb0470","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"9349","key":"10.1016\/j.vph.2017.09.001_bb0475","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vph.2017.09.001_bb0480","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0485","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.vph.2017.09.001_bb0490","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0495","article-title":"Lengthening of QT interval by antipsychotic drugs","volume":"77","author":"Haverkamp","year":"2006","journal-title":"Nervenarzt"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0500","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.12m08001","article-title":"Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization","volume":"74","author":"Jin","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.vph.2017.09.001_bb0505","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsade de pointes and sudden death","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.vph.2017.09.001_bb0510","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5694\/j.1326-5377.2006.tb00272.x","article-title":"Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes","volume":"184","author":"Isbister","year":"2006","journal-title":"Med. J. Aust."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0515","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/JCP.0b013e3181e5c14c","article-title":"Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes","volume":"30","author":"Isbister","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1258\/rsmmsl.48.2.173","article-title":"Fatality due to amisulpride toxicity: a case report","volume":"48","author":"Lynch","year":"2008","journal-title":"Med. Sci. Law"},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0525","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/096032719501400310","article-title":"Amisulpride poisoning: a report on two cases","volume":"14","author":"Tracqui","year":"1995","journal-title":"Hum. Exp. Toxicol."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0530","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1742-6723.2005.00734.x","article-title":"Two cases of amisulpride overdose: a cause for prolonged QT syndrome","volume":"17","author":"Ward","year":"2005","journal-title":"Emerg. Med. Australas."},{"issue":"8","key":"10.1016\/j.vph.2017.09.001_bb0535","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003088-200847080-00003","article-title":"Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole","volume":"47","author":"Mallikaarjun","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"18","key":"10.1016\/j.vph.2017.09.001_bb0540","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00213-015-4024-9","article-title":"The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach","volume":"232","author":"Polcwiartek","year":"2015","journal-title":"Psychopharmacology"},{"issue":"118","key":"10.1016\/j.vph.2017.09.001_bb0545","article-title":"Clozapine, immunosuppressants and renal transplantation","volume":"23","author":"Lim","year":"2016","journal-title":"Asian J. Psychiatr."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0550","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","article-title":"Antipsychotic drugs and QT prolongation","volume":"20","author":"Stollberger","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0555","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","article-title":"Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic","volume":"4","author":"Citrome","year":"2011","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"key":"10.1016\/j.vph.2017.09.001_bb0560","article-title":"Pharmacokinetics and pharmacodynamics of Lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","author":"Greenberg","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0565","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.vph.2017.09.001_bb0570","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4088\/JCP.v62n0310","article-title":"Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis","volume":"62","author":"Czekalla","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.vph.2017.09.001_bb0575","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0580","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0585","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2710.2011.01271.x","article-title":"Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers","volume":"37","author":"Mahatthanatrakul","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"issue":"12","key":"10.1016\/j.vph.2017.09.001_bb0590","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1139\/cjpp-2013-0185","article-title":"Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats","volume":"91","author":"Aboul-Fotouh","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"2","key":"10.1016\/j.vph.2017.09.001_bb0595","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/JCP.0b013e318283983f","article-title":"Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials","volume":"33","author":"Gopal","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0600","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gps.1792","article-title":"The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials","volume":"22","author":"Katz","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0605","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11599010-000000000-00000","article-title":"Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data","volume":"26","author":"Camm","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.vph.2017.09.001_bb0610","first-page":"Cd001718","article-title":"Depot fluspirilene for schizophrenia","volume":"1","author":"Abhijnhan","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0615","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(01)00336-X","article-title":"A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol","volume":"59","author":"Su","year":"2003","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.vph.2017.09.001_bb0620","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","article-title":"The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?","volume":"5","author":"Meyer-Massetti","year":"2010","journal-title":"J. Hosp. Med."},{"issue":"5","key":"10.1016\/j.vph.2017.09.001_bb0625","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0630","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.vph.2017.09.001_bb0635","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/JCP.0b013e318191c6a8","article-title":"Psychotropic drugs associated with corrected QT interval prolongation","volume":"29","author":"van Noord","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.vph.2017.09.001_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2013.07.272","article-title":"PP232-acute toxicity profile of pipamperone in overdose: a consecutive case series","volume":"35","author":"Hofer","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.vph.2017.09.001_bb0645","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2011.4542","article-title":"An unusual presentation of cortical venous thrombosis and its association with typical antipsychotics","volume":"2011","author":"Andole","year":"2011","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.vph.2017.09.001_bb0650","article-title":"Zuclopenthixol versus placebo for schizophrenia","volume":"12","author":"Lacey","year":"2015","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:21:08Z","timestamp":1750868468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189117301726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":130,"alternative-id":["S1537189117301726"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2017.09.001","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}